Overall, these studies suggest that CSF Aβ42 and P-tau reflect the intensity of the AD process (stage markers) with amyloid and Tau PET, by contrast, reflecting how the density and distribution of AD pathology [124, 125] (i.e., how far the disease has progressed; stage marker) [114]. This evidence concerns the gene MAPT and Alzheimer disease.